Navigation Links
Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Date:4/11/2008

TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Targeting mutant p53 protein and tumor vasculature: An effective

combination therapy for advanced breast tumors" (Abstract #2341, New

Targets 1: Mechanisms Session) - Poster session scheduled for Monday,

April 14, 2008 from 8:00 am to 12:00 pm.

-- "An immunocytokine that binds to phosphatidylserine generates an

effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor

Vaccines Session) - Poster session scheduled for Monday, April 14,

2008 from 1:00 pm to 5:00 pm.

-- "Combination of a monoclonal anti-phosphatidylserine antibody with

docetaxel strongly inhibits the growth and metastasis of

hormone-refractory prostate cancers in mice" (Abstract #2551, New

Approaches to Biological Therapy Session) - Oral presentation

scheduled for Monday, April 14, 2008 at 2:10 pm.

-- "Antibody targeting of phosphatidylserine produces a cytokine

microenvironment that enhances innate anti-tumor immune responses"

(Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 from

8:00 am to 12:00 pm.

Abstracts and information about the AACR and its Annual Meeting may be found at http://www.aacr.org.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
2. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
3. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
8. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... , ... Diversity focused business accelerator, The Refinery , announced today they ... the top technology-driven, women-led startups in Boston, MA, New Haven/Hamden, CT, and Newark, NJ. ... going on that week – in Boston, it will be part of the City ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... examining the effects of exoskeleton-assisted walking on gait parameters and neuromuscular activity ... "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking session" (doi:10.1080.10790268.2017.1314900) was ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... and building management solutions, announced today the opening of an office in Taipei, ... and the Greater China region, while developing new relationships in the region. Located ...
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling ... early-stage tech companies. “Grit” author Angela Duckworth and her team at Character Lab ... is Cooley, an international law firm with decades of experience supporting high-growth companies ...
Breaking Biology Technology:
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):